
    
      Primary Objective: To investigate ranibizumab's benefit on prevention of early postoperative
      vitreous haemorrhage in PDR-DME patients receiving vitrectomy.

      Secondary Objective:To investigate ranibizumab's additional benefit on visual improvement,
      facilitation of surgery and postoperative outcomes in PDR-DME patients receiving vitrectomy.

      Study design: This study is a prospective, randomized, single-blinded, blank-controlled,
      multi-center clinical trial that requires vitrectomy for PDR-DME patients.
    
  